ViewRay, Inc. (VRAYQ)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0001 - Volume
3,000 - Avg. Volume
0 - Market Cap (intraday)
1,834 - Beta (5Y Monthly) -52.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado. On July 16, 2023, ViewRay, Inc., alongwith its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay , Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.
www.viewray.comRecent News: VRAYQ
View MorePerformance Overview: VRAYQ
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRAYQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRAYQ
View MoreValuation Measures
Market Cap
1.83k
Enterprise Value
3.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-104.30%
Return on Assets (ttm)
-25.29%
Return on Equity (ttm)
-108.91%
Revenue (ttm)
105.86M
Net Income Avi to Common (ttm)
-110.42M
Diluted EPS (ttm)
-0.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
81.29M
Total Debt/Equity (mrq)
154.07%
Levered Free Cash Flow (ttm)
-72.17M